Literature DB >> 24509443

Tyrosine kinases: the molecular switch for inflammasome activation.

Federica Laudisi, Elena Viganò, Alessandra Mortellaro.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24509443      PMCID： PMC4003385          DOI： 10.1038/cmi.2014.4

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN： 1672-7681            Impact factor:   11.530


× No keyword cloud information.
  10 in total

1.  An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents.

Authors:  Mark C Genovese; Arthur Kavanaugh; Michael E Weinblatt; Charles Peterfy; Julie DiCarlo; Michael L White; Maryann O'Brien; Elliott B Grossbard; Daniel B Magilavy
Journal:  Arthritis Rheum       Date:  2011-02

2.  Deal watch: high hopes for oral SYK inhibitor in rheumatoid arthritis.

Authors:  Monica Hoyos Flight
Journal:  Nat Rev Drug Discov       Date:  2012-01-03       Impact factor: 84.694

Review 3.  Targeting non-malignant disorders with tyrosine kinase inhibitors.

Authors:  Friedrich Grimminger; Ralph T Schermuly; Hossein A Ghofrani
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

Review 4.  Caspase-1-induced pyroptotic cell death.

Authors:  Edward A Miao; Jayant V Rajan; Alan Aderem
Journal:  Immunol Rev       Date:  2011-09       Impact factor: 12.988

Review 5.  Pyroptosis: host cell death and inflammation.

Authors:  Tessa Bergsbaken; Susan L Fink; Brad T Cookson
Journal:  Nat Rev Microbiol       Date:  2009-02       Impact factor: 60.633

6.  Pralnacasan, an inhibitor of interleukin-1beta converting enzyme, reduces joint damage in two murine models of osteoarthritis.

Authors:  K Rudolphi; N Gerwin; N Verzijl; P van der Kraan; W van den Berg
Journal:  Osteoarthritis Cartilage       Date:  2003-10       Impact factor: 6.576

7.  The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta.

Authors:  Fabio Martinon; Kimberly Burns; Jürg Tschopp
Journal:  Mol Cell       Date:  2002-08       Impact factor: 17.970

Review 8.  Treating inflammation by blocking interleukin-1 in humans.

Authors:  Charles A Dinarello; Jos W M van der Meer
Journal:  Semin Immunol       Date:  2013-11-23       Impact factor: 11.130

Review 9.  The rhapsody of NLRPs: master players of inflammation...and a lot more.

Authors:  Lia Paola Zambetti; Federica Laudisi; Ginevra Licandro; Paola Ricciardi-Castagnoli; Alessandra Mortellaro
Journal:  Immunol Res       Date:  2012-09       Impact factor: 4.505

10.  Phosphorylation of the adaptor ASC acts as a molecular switch that controls the formation of speck-like aggregates and inflammasome activity.

Authors:  Hideki Hara; Kohsuke Tsuchiya; Ikuo Kawamura; Rendong Fang; Eduardo Hernandez-Cuellar; Yanna Shen; Junichiro Mizuguchi; Edina Schweighoffer; Victor Tybulewicz; Masao Mitsuyama
Journal:  Nat Immunol       Date:  2013-11-03       Impact factor: 25.606
  10 in total
  2 in total

1.  Inhibition of spleen tyrosine kinase activation ameliorates inflammation, cell death, and steatosis in alcoholic liver disease.

Authors:  Terence N Bukong; Arvin Iracheta-Vellve; Banishree Saha; Aditya Ambade; Abhishek Satishchandran; Benedek Gyongyosi; Patrick Lowe; Donna Catalano; Karen Kodys; Gyongyi Szabo
Journal:  Hepatology       Date:  2016-07-22       Impact factor: 17.425

2.  Homotypic CARD-CARD interaction is critical for the activation of NLRP1 inflammasome.

Authors:  Zhihao Xu; Ying Zhou; Muziying Liu; Huan Ma; Liangqi Sun; Ayesha Zahid; Yulei Chen; Rongbin Zhou; Minjie Cao; Dabao Wu; Weidong Zhao; Bofeng Li; Tengchuan Jin
Journal:  Cell Death Dis       Date:  2021-01-11       Impact factor: 8.469
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.